Authors: Sacchi, S Federico, M Dastoli, G Fiorani, C Vinci, G Clo, V Casolari, B

Citation: S. Sacchi et al., Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab, CR R ONC H, 37(1), 2001, pp. 13-25

Authors: Sacchi, S Federico, M Vitolo, U Boccomini, C Vallisa, D Baldini, L Petrini, M Rupoli, S Di Raimondo, F Merli, F Liso, V Tabilio, A Saglio, G Vinci, G Brugiatelli, M Dastoli, G

Citation: S. Sacchi et al., Clinical activity and safety of combination immunotherapy with interferon-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma, HAEMATOLOG, 86(9), 2001, pp. 951-958

Authors: Toma, S Raffo, P Nicolo, G Canavese, G Margallo, E Vecchio, C Dastoli, G Iacona, I Regazzi-Bonora, M

Citation: S. Toma et al., Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients, INT J ONCOL, 17(5), 2000, pp. 991-1000

Authors: Magni, M Di Nicola, M Devizzi, L Matteucci, P Lombardi, F Gandola, L Ravagnani, F Giardini, R Dastoli, G Tarella, C Pileri, A Bonadonna, G Gianni, AM

Citation: M. Magni et al., Successful in vivo purging of CD34-containing peripheral blood harvests inmantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion, BLOOD, 96(3), 2000, pp. 864-869

Authors: Oliveri, F Santantonio, T Bellati, G Colombatto, P Mels, GC Carriero, L Dastoli, G Pastore, G Ideo, G Bonino, F Brunetto, MR

Citation: F. Oliveri et al., Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon, AM J GASTRO, 94(5), 1999, pp. 1366-1372